June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Customized corneal crosslinking for halting the progression of keratectasia
Author Affiliations & Notes
  • Theo G Seiler
    IROC AG, Zurich, Switzerland
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Isaak Raphael Fischinger
    IROC AG, Zurich, Switzerland
    Ophthalmology, Technical University of Munich, Munich, Germany
  • Tobias Koller
    IROC AG, Zurich, Switzerland
  • Theo Seiler
    IROC AG, Zurich, Switzerland
  • Footnotes
    Commercial Relationships Theo G Seiler, None; Isaak Fischinger, None; Tobias Koller, None; Theo Seiler, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3018. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Theo G Seiler, Isaak Raphael Fischinger, Tobias Koller, Theo Seiler; Customized corneal crosslinking for halting the progression of keratectasia . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3018.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate efficacy of tomography-customized corneal crosslinking and to prove hypothesis of focal weakening in primary corneal ectasia.

Methods: In a prospective study, 22 eyes of 22 patients were treated with customized crosslinking for halting the progression of keratectasia and followed for 12 months. Standard 0.1% Riboflavin in 15% Dextran was applied for 30 min. The irradiation-profiles were centred on the maximum posterior float with energy fluencies of 10mW/cm². The total energy applied to the corneas had a maximum of 15J/cm². BSCVA, Scheimpflug imaging, topography, endothelial cell count, AS-OCT and slit lamp examination were collected as pre- and postoperative parameters.

Results: BSCVA increased by -0.08 ± 0.16logMAR (p=0.17). No eye had a loss of more than 1 Snellen line. Kmax decreased by -0.70 ± 1.08D (p=0.11) as well as the posterior float went down by -8 ± 7µm (p=0.01). Corneal pachymetry decreased by -9 ± 11µm (p=0.05), the endothelial cell count did not change significantly (p=0.44). Average epithelium healing time was 2.63 ± 0.48 days. One eye showed sterile infiltrates, no other complications occurred.

Conclusions: Tomography-customized corneal crosslinking is a promising approach for halting the progression of keratectasia. Due to the smaller abrasion zone necessary, customized CXL presents a less invasive procedure for the patient. For the first time a flattening of the posterior float has been observed, which may be a result of the reversal of a focal weakening of the cornea. Larger and longer study groups are needed to prove safety and validate the efficacy.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×